Camurus Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

camurus.com

Location:

Lund, Sweden

Total Funding:N/A

Industry:Pharma

Founded:1991

Lead Investor(s):N/A

Estimated Revenue & Financials

Camurus's estimated annual revenue is currently $25.5M per year.
Camurus's estimated revenue per employee is $201,000

Employee Data

Camurus has 127 Employees.
Camurus grew their employee count by 38% last year.
Camurus currently has 1 job openings.

Camurus Competitors

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Online Review	Pricing
Advertise Here
#1 Pharmetheus	$10.7M	53	51%	N/A	-	N/A
#2 Oncopeptides AB	$13.5M	67	91%	N/A	-	N/A
#3 KeyPlants AB	$10.9M	54	26%	N/A	-	N/A
#4 Pharmadule Mori...	$15.5M	77	13%	N/A	-	N/A
#5 Camurus	$25.5M	127	38%	N/A	-	N/A
#6 ComplyiT AB	$20.7M	103	12%	N/A	-	N/A
#7 Oncopeptides AB	$33.6M	167	169%	N/A	-	N/A
#8 Karo Pharma	$38.6M	192	48%	N/A	-	N/A

Missing a competitor? Contribute!?

Submit

Show More Pharma Companies

What Is Camurus?

Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company's shares are listed on Nasdaq Stockholm under the ticker CAMX.

keywords:N/A

127

Number of Employees

$25.5M

Revenue (est)

Current Jobs

38%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Camurus News

09/03/2019 - Camurus: Australian Minister for Health Announced PBS ...

LUND, Sweden, Aug. 26, 2019 /PRNewswire/ -- The Australian Federal Health Minister Greg Hunt announced on Sunday that Camurus' ...

09/08/2019 - Camurus AB (publ)'s (STO:CAMX) Shift From Loss To Profit

Camurus AB (publ)'s (STO:CAMX): Camurus AB (publ), a research-based pharmaceutical company, develops and commercializes ...

09/03/2019 - Camurus AB (publ) (OM:CAMX) Year Over Year With Profit Growth of 0.37383: Is it Time to Buy?

Camurus AB (publ) (OM:CAMX) has posted year over year net profit growth of 0.37383. The net profit number is the nuts and bolts of a firm's ...